Share on StockTwits
 

Shares of NPS Pharmaceuticals (NASDAQ:NPSP) hit a new 52-week high on Wednesday, Stock Ratings News reports. The company traded as high as $37.74 and last traded at $36.99, with a volume of 1,192,936 shares trading hands. The stock had previously closed at $37.12.

A number of research firms have recently commented on NPSP. Analysts at TheStreet upgraded shares of NPS Pharmaceuticals from a “sell” rating to a “hold” rating in a research note to investors on Monday, January 20th. Separately, analysts at Brean Capital raised their price target on shares of NPS Pharmaceuticals from $36.00 to $41.00 in a research note to investors on Thursday, January 9th. Finally, analysts at Canaccord Genuity raised their price target on shares of NPS Pharmaceuticals from $35.00 to $42.00 in a research note to investors on Monday, January 6th. They now have a “buy” rating on the stock. Three research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $37.69.

NPS Pharmaceuticals has a 52 week low of $7.35 and a 52 week high of $37.43. The stock has a 50-day moving average of $31.27 and a 200-day moving average of $27.04. The company’s market cap is $3.751 billion.

NPS Pharmaceuticals (NASDAQ:NPSP) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.01) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.02) by $0.01. The company had revenue of $39.20 million for the quarter, compared to the consensus estimate of $38.40 million. During the same quarter last year, the company posted ($0.04) earnings per share. NPS Pharmaceuticals’s revenue was up 45.2% compared to the same quarter last year. Analysts expect that NPS Pharmaceuticals will post $-0.21 EPS for the current fiscal year.

NPS Pharmaceuticals, Inc (NASDAQ:NPSP) is a clinical-stage biopharmaceutical company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.